参考文献
　　[1]Miyasaka Y，Barnes ME，Gersh BJ，et a1．Secular trends in incidence of atrial fibrillation in Olmsted County Minnesota， 1980 to 2000 and implications on the projections for future prevalence. Circulation，2006;114：l19-125.
　　[2]Rosiak M， Dziuba M， Chudzik M，et al. Risk factors for atrial fibrillation: Not always severe heart disease， not always so ‘lonely’. Cardiology J，2010;17，5:437-442.
　　[3]Wang TJ，Parise H，k vy D，et a1．Obesity and the risk of new-onset atrial fibrillation. JAMA，2004;292：2471-2477.
　　[4]Wanahita N， Messerli FH， Bangalore S， et al. Atrial fibrillation and obesity results of a meta-analysis. Am Heart J， 2008;155:310–315.
　　[5]Girerd N， Pibarot P， Fournier D， et al. Middle-aged men with increased waist circumference and elevated c-reactive protein level are at high risk of postoperative atrial fibrillation following coronary artery bypass grafting surgery. Eur Heart J，2009;30:1270–1278.
　　[6]Echahidi N， Mohty D， Pibarot P， et al. Obesity and metabolic syndrome are independent risk factors for atrial fibrillation after coronary artery bypass graft surgery. Circulation，2007;116 (Supplement I):I213–I219.
　　[7]Filardo G，Hamilton C，Hamman B，et al.Relation of obesity to atrial fibrillation after isolated coronary artery bypass grafting. Am J Cardiol， 2009;103:663–666.
　　[8]Frost L， Hune LJ， Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet， Cancer， and Health Study. Am J Med，2005;118(5):489–495.
　　[9] Dublin S， French B， Glazer NL， et al. Risk of new-onset atrial fibrillation in relation to body mass index. Arch Intern Med， 2006;166(21):2322–2328.
　　[10]Tedrow UB， Cohen D， Ridker PM， et al. The long- and  short-term impact of elevated body mass index on the risk of new atrial fibrillation. J Am Coll Cardiol ，2010; 55:2319–2327.
　　[11]Ayer JG， Almagragy HS， Patel AA， et al. Body mass index is an independent determinant of left atrial size. Heart Lung and Circ， 2008;17:19–24.
　　[12]Nicolaou VN， Papadakis JE， Dermitzakis G， et al. Effect of obesity on atrial size in older women with nonvalvular paroxysmal atrial fibrillation. Aging Clin Exp Res， 2008， 21:344–348.
　　[13] Kosar F， Aksoy Y， Ari F， et al. P-wave duration and dispersion in obese subjects. Ann Noninvasive Electrocardiol， 2008; 13:3–7.
　　[14] Chung MK， Martin DO， Sprecher D， et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation， 2001;104:2886–2891.
　　[15]Lin YK， Chen YJ， Chen SA. Potential atrial arrhythmogenicity of adipocytes:implications of the genesis of atrial fibrillation. Med Hypotheses ，2010;74:1026–1029.
　　[16]Cha YM， Friedman PA， Asirvatham SJ， et al. Catheter ablation for atrial fibrillation in patients with obesity. Circulation ，2008;117:2583–2590.
　　[17]Chilukuri K， Dalal D， Gadrey S， et al. A prospective study evaluating the role of obesity and obstructive sleep apnea for outcomes after catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol，2010;21:521–525.
　　[18]Uretsky S， Messerli FH， Bangalore S， et al. Obesity paradox in patients with hypertension and coronary artery disease.  Am J Med， 2007;120:863-870.
　　[19]Lavie CJ， Milani RV， Ventura HO. Obesity， heart disease， and favorable prognosis—truth or paradox?  Am J Med， 2007;120:825-826.
　　[20]Galal W， van Gestel YR， Hoeks SE， et al. The obesity paradox in patients with peripheral arterial disease. Chest， 2008;134:925-930.
　　[21]Lavie CJ， Ventura HO， Milani RV. The “obesity paradox”: is smoking/lung disease the explanation? Chest， 2008;134:896-898.
　　[22]Lavie CJ， Milani RV， Ventura HO. Obesity and cardiovascular disease:risk factor， paradox， and impact of weight loss. J Am Coll Cardiol， 2009;53:1925-1932.
　　[23]McAuley P， Myers J， Abella J，et al. Body mass， fitness and survival in veteran patients: another obesity paradox? Am J Med，2007;120:518-524.
　　[24]Badheka AO， Rathod A， Kizilbash MA，et al.Influence of obesity on outcomes in atrial fibrillation:yet another obesity paradox. Am J Med，2010;123:646-651.
　　[25] Horwich TB， Fonarow GC. Reverse epidemiology beyond dialysis patients: chronic heart failure， geriatrics， rheumatoid arthritis. COPD，and AIDS， Semin Dial， 2007;20:549-553.
　　[26]Kalantar-Zadeh K， Block G， Humphreys MH，et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int，2003;63:793-808.
　　[27]Issac TT， Dokainish H， Lakkis NM. Role of inflammation ininitiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol，2007;50:2021-2028.
　　[28]Lee SH， Chen YC， Chen YJ， et al. Tumor necrosis factor-alpha alters calcium handling and increases arrhythmogenesis of pulmonary vein cardiomyocytes.  Life Sci ，2007 ;80:1806-1815.
　　[29]Sawaya SE， Rajawat YS， Rami TG， et al. Downregulation of connexin40 and increased prevalence of atrial arrhythmias in transgenic mice with cardiac-restricted overexpression of tumor necrosis factor. Am J Physiol Heart Circ Physiol，2007;292:H1561-H1567.
　　[30]Mohamed-Ali V， Goodrick S， Bulmer K， et al. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol， 1999;277:E971-E975.
　　[31]Novo G， Guttilla D， Fazio G， et al. The role of the  renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS. Br J Clin Pharmacol， 2008;66:345-351.
　　[32]Weber MA， Neutel JM， Smith DH. Contrasting clinical properties and exercise responses in obese and lean hypertensive patients. J Am Coll Cardiol， 2001;37:169-174.
　　[33]Rossi A， Enriquez-Sarano M， Burnett JC Jr， et al. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic Study. J Am Coll Cardiol， 2000;35:1256-1262.
　　[34]Rienstra M， Van Gelder IC， Van den Berg MP， et al. Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NTpro) BNP. Europace， 2006;8:482-487.
　　[35]Wang TJ， Larson MG， Levy D， et al. Impact of obesity on plasma natriuretic peptide levels. Circulation， 2004;109:594-600.
　　[36]Rauchhaus M， Coats AJ， Anker SD. The endotoxin-lipoprotein hypothesis. Lancet， 2000;356(9233):930-933.
　　[37]Boos CJ， Lip GY， Jilma B. Endotoxemia， inflammation， and atrial fibrillation. Am J Cardiol， 2007;100:986-988.
　　[38]Horwich TB， Fonarow GC， Hamilton MA， et al. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol，2001;38:789-795.
　　[39]Niraj A， Pradhan J， Fakhry H， et al. Severity of coronary artery disease in obese patients undergoing coronary angiography: “obesity paradox”revisited. Clin Cardiol， 2007;30:391-396.